Literature DB >> 18292465

Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Marzieh Salehi1, Benedikt A Aulinger, David A D'Alessio.   

Abstract

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic beta-cells or a reduction in beta-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on beta-cell physiology as well as by expanding or at least maintaining beta-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18292465      PMCID： PMC2528856          DOI： 10.1210/er.2007-0031

Source DB:  PubMed          Journal:  Endocr Rev        ISSN： 0163-769X            Impact factor:   19.871


  161 in total

Review 1.  Islet growth and development in the adult.

Authors:  S Bonner-Weir
Journal:  J Mol Endocrinol       Date:  2000-06       Impact factor: 5.098

Review 2.  Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

Authors:  S E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

3.  Neural regulation of glucagon-like peptide-1 secretion in pigs.

Authors:  Lene Hansen; Sarah Lampert; Hitoshi Mineo; Jens J Holst
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-11       Impact factor: 4.310

Review 4.  The replication of beta cells in normal physiology, in disease and for therapy.

Authors:  Peter C Butler; Juris J Meier; Alexandra E Butler; Anil Bhushan
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-11

5.  Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion.

Authors:  A S Rocca; P L Brubaker
Journal:  Endocrinology       Date:  1999-04       Impact factor: 4.736

6.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

Authors:  L A Scrocchi; T J Brown; N MaClusky; P L Brubaker; A B Auerbach; A L Joyner; D J Drucker
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

7.  Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells.

Authors:  Elizabeth J Abraham; Colin A Leech; Julia C Lin; Henryk Zulewski; Joel F Habener
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

8.  Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells.

Authors:  Atsushi Nakagawa; Hanae Satake; Hajime Nakabayashi; Makoto Nishizawa; Keisuke Furuya; Shigeru Nakano; Toshikazu Kigoshi; Kohzo Nakayama; Kenzo Uchida
Journal:  Auton Neurosci       Date:  2004-01-30       Impact factor: 3.145

Review 9.  Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications.

Authors:  M Y Donath; P A Halban
Journal:  Diabetologia       Date:  2004-02-07       Impact factor: 10.122

10.  Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus.

Authors:  T Krarup; N Saurbrey; A J Moody; C Kühl; S Madsbad
Journal:  Metabolism       Date:  1987-07       Impact factor: 8.694
View more
  29 in total

Review 1.  Proteostasis strategies for restoring alpha1-antitrypsin deficiency.

Authors:  Marion Bouchecareilh; Juliana J Conkright; William E Balch
Journal:  Proc Am Thorac Soc       Date:  2010-11

2.  Clinical guideline: management of gastroparesis.

Authors:  Michael Camilleri; Henry P Parkman; Mehnaz A Shafi; Thomas L Abell; Lauren Gerson
Journal:  Am J Gastroenterol       Date:  2012-11-13       Impact factor: 10.864

3.  Temporal and Regional Expression of Glucose-Dependent Insulinotropic Peptide and Its Receptor in Spinal Cord Injured Rats.

Authors:  Ana Beatriz W Marcos; Stefania Forner; Alessandra C Martini; Eliziane S Patrício; Julia R Clarke; Robson Costa; João Felix-Alves; Vilberto José Vieira; Edinéia Lemos de Andrade; Tânia Longo Mazzuco; João Batista Calixto; Claudia Pinto Figueiredo
Journal:  J Neurotrauma       Date:  2015-12-23       Impact factor: 5.269

4.  Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide.

Authors:  Scott B Widenmaier; Arthur V Sampaio; T Michael Underhill; Christopher H S McIntosh
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

5.  Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

Authors:  David A D'Alessio; Amanda M Denney; Linda M Hermiller; Ronald L Prigeon; Julie M Martin; William G Tharp; Monica Liqueros Saylan; Yanling He; Beth E Dunning; James E Foley; Richard E Pratley
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

6.  A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control.

Authors:  Scott B Widenmaier; Su-Jin Kim; Gary K Yang; Thomas De Los Reyes; Cuilan Nian; Ali Asadi; Yutaka Seino; Timothy J Kieffer; Yin Nam Kwok; Christopher H S McIntosh
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

Review 7.  The proteostasis boundary in misfolding diseases of membrane traffic.

Authors:  Darren M Hutt; Evan T Powers; William E Balch
Journal:  FEBS Lett       Date:  2009-08-20       Impact factor: 4.124

8.  Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery.

Authors:  M M Swarbrick; K L Stanhope; I T Austrheim-Smith; M D Van Loan; M R Ali; B M Wolfe; P J Havel
Journal:  Diabetologia       Date:  2008-08-15       Impact factor: 10.122

Review 9.  NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse.

Authors:  Owen P McGuinness; Julio E Ayala; Maren R Laughlin; David H Wasserman
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-28       Impact factor: 4.310

10.  Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB.

Authors:  Daniel A Cunha; Laurence Ladrière; Fernanda Ortis; Mariana Igoillo-Esteve; Esteban N Gurzov; Roberto Lupi; Piero Marchetti; Décio L Eizirik; Miriam Cnop
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.